Adhesin as immunogen against enterotoxigenic Escherichia coli
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The inventive subject matter relates to the methods for the induction of immunity and prevention of diarrhea resulting from Escherichia coli. The inventive subject matter also relates to the use Escherichia coli adhesins as immunogens and to the construction of conformationally stability and protease resistant Escherichia coli adhesin constructs useful for inducing immunity to Escherichia coli pathogenic bacteria. The methods provide for the induction of B-cell mediated immunity and for the induction of antibody capable of inhibiting the adherence and colonization of Escherichia coli, including enterotoxigenic Escherichia coli, to human cells.
Core Innovation
The inventive subject matter relates to methods for inducing immunity and preventing diarrhea caused by Escherichia coli by using Escherichia coli adhesins as immunogens. The invention specifically involves the construction of conformationally stable and protease resistant Escherichia coli adhesin constructs that are useful for inducing immunity against pathogenic Escherichia coli, including enterotoxigenic strains. The methods focus on inducing B-cell mediated immunity and generating antibodies capable of inhibiting adherence and colonization of Escherichia coli to human cells.
The background identifies the problem that existing vaccines against diarrheagenic bacteria such as enterotoxigenic Escherichia coli (ETEC) are not adequately efficacious, especially in resource-limited countries where diarrheal diseases are prevalent. Enterotoxigenic Escherichia coli cause disease by adherence to small intestinal epithelial cells through bundle-forming fimbriae called colonization factors (CFs), with adhesion being a key step in pathogenesis. There are multiple CFs, including class 5 fimbriae such as colonization factor antigen I (CFA/I), which is well characterized as an important adhesin. The problem lies in developing effective vaccines that target the precise adhesive components responsible for bacterial colonization.
The invention addresses this problem by identifying that the minor fimbrial subunits (adhesins) of class 5 fimbriae serve as the receptor-binding moiety crucial for adherence. The invention provides methods of inducing an immune response against ETEC by using these fimbrial adhesin components as immunogens rather than whole fimbriae or bacteria. Furthermore, it introduces the construction of polypeptide constructs that provide conformational stability and protease resistance through donor strand complementation, whereby a donor β-strand from a major fimbrial subunit stabilizes the adhesin polypeptide. These stabilized constructs are more immunogenic and capable of inducing effective immunity.
Claims Coverage
The patent contains multiple independent claims covering immunogenic compositions comprising adhesin polypeptides linked to major fimbrial subunits and methods of inducing immune responses using these compositions or recombinant host cells.
Immunogenic composition of adhesin linked to major fimbrial subunit
A composition comprising a complex of a whole or antigenic polypeptide fragment of Escherichia coli fimbrial adhesin linked at its C-terminus to a linker which is operatively linked at its C-terminus to a whole or antigenic polypeptide fragment of Escherichia coli major structural fimbrial subunit, all derived from class 5 fimbriae.
Use of specific adhesins and major subunits
The fimbrial adhesin is selected from CfaE, CsfD, CsuD, CooD, CosD, CsdD, CsbD, and CotD. The major structural fimbrial subunit is selected from CfaB, CsfA, CsuA1, CsuA2, CooA, CosA, CsbA, CsdA, and CotA, with specified polypeptide fragments (SEQ ID Nos.).
Conformational stability and protease resistance conferred by major subunit
The polypeptide fragment of the major structural fimbrial subunit confers conformational stability and protease resistance to the adhesin polypeptide fragment.
Method of inducing immune response by administering immunogenic composition
Administration of the immunogenic composition at a unit dose of 50 μg to 1 mg for priming followed by boosting doses with the same range, inducing immunoglobulin production capable of binding Escherichia coli fimbriae and inhibiting bacterial adherence and colonization of mucosal epithelial cells.
Method of inducing immune response by administering recombinant host bacterial cells
Administration of host bacterial cells containing the immunogenic composition expressing the adhesin polypeptide at 50 μg to 1 mg per dose for priming and boosting induces immunity. Host bacterial cells can be live attenuated or killed and include Escherichia coli, Shigella, Campylobacter, Salmonella, and Vibrio species.
Immunogenic composition comprising CS3 adhesin linked to donor strand
A composition comprising a whole or antigenic polypeptide fragment of Escherichia coli coli surface antigen 3 (CS3) linked at the C-terminus to a linker operatively linked to a donor strand polypeptide of CS3, specifically CstH polypeptides or fragments thereof.
The independent claims collectively cover immunogenic compositions consisting of stabilized adhesion polypeptide constructs formed by linking Escherichia coli fimbrial adhesins to major structural fimbrial subunits derived from class 5 fimbriae and CS3 fimbriae, as well as methods for inducing immune responses by administering these compositions or recombinant bacterial hosts expressing such polypeptides. These claims emphasize the conformationally stable, protease resistant constructs that elicit antibodies inhibiting E. coli adherence and colonization.
Stated Advantages
Induction of superior and more efficacious immunity against diarrheagenic bacteria by targeting adhesin subunits rather than whole fimbriae or whole bacteria, possibly requiring less antigen to elicit immunity.
Conformationally stable and protease resistant adhesin polypeptide constructs ensure maximum immunogenicity and improved efficacy of vaccines.
Ability to induce B-cell mediated immunity and production of antibodies capable of inhibiting bacterial colonization and adherence to host cells.
The stabilized constructs yield higher titers of functional antibodies, as demonstrated in immunization experiments.
Documented Applications
Induction of immunity against enterotoxigenic Escherichia coli by administration of immunogenic compositions containing stabilized class 5 fimbriae adhesin polypeptides.
Use of the immunogenic compositions or recombinant bacterial host cells expressing these adhesin constructs as vaccines to prevent adherence and colonization of E. coli to human mucosal epithelial cells.
Administration routes for immunization include oral, nasal, subcutaneous, intradermal, transdermal, transcutaneous, intramuscular, or rectal delivery.
Vaccines formulated from the adhesin constructs can be applied to resource-limited regions where diarrheal disease burden is high to prevent diarrhea caused by diarrheagenic E. coli.
Interested in licensing this patent?